ArticleNature communications2024
Single missense mutations in Vi capsule synthesis genes confer hypervirulence to Salmonella Typhi.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The Manipulation of Host Cells byInternational journal of molecular sciences · 2026Review
- Global genomic surveillance uncovers emergence and spatiotemporal patterns of World Health Organization priority antibiotic resistance in invasive Salmonella.Nature communications · 2026Article
- OmpW-mediated sensing of MUC2 GalNAc contributes to the ileal tropism of Salmonella Typhi.Cell reports · 2026Article
- Molecular epidemiology and antimicrobial resistance of extended-spectrum beta-lactamases-producingJAC-antimicrobial resistance · 2026Article
- Genetic control of Group 3 (K96) capsule synthesis and complement resistance in extraintestinal pathogenicmSphere · 2026Article
- Article
- Genomic analysis ofMicrobial genomics · 2026Article
- Article
- A mouse model for studying chronicmBio · 2026Article
- A new mouse model of typhoid fever usingmBio · 2026Article
- Adaptive microevolution in CC17Frontiers in cellular and infection microbiology · 2026Article
- Human gut microbiota-derived antimicrobials against Salmonella Typhi: diversity, mechanisms, and therapeutic potential.Archives of microbiology · 2025Review
- Molecular basis of the hepatobiliary tropism of typhoid toxin promotingScience advances · 2025Article
- Assessing Salmonella Typhi Pathogenicity and Prevention: The Crucial Role of Vaccination in Combating Typhoid Fever.International journal of molecular sciences · 2025Review
- Propionylation of Fis K32 inFuture microbiology · 2025Article
- Genetic heterogeneity in theMicrobial genomics · 2024Article
- Antimicrobial properties of tomato juice and peptides against typhoidalMicrobiology spectrum · 2024Article
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
Many bacterial pathogens, including the human exclusive pathogen Salmonella Typhi, express capsular polysaccharides as a crucial virulence factor. Here, through S. Typhi whole genome sequence analyses and functional studies, we found a list of single point mutations that make S. Typhi hypervirulent. We discovered a single point mutation in the Vi biosynthesis enzymes that control Vi polymerization or acetylation is enough to result in different capsule variants of S. Typhi. All variant strains are pathogenic, but the hyper Vi capsule variants are particularly hypervirulent, as demonstrated by the high morbidity and mortality rates observed in infected mice. The hypo Vi capsule variants have primarily been identified in Africa, whereas the hyper Vi capsule variants are distributed worldwide. Collectively, these studies increase awareness about the existence of different capsule variants of S. Typhi, establish a solid foundation for numerous future studies on S. Typhi capsule variants, and offer valuable insights into strategies to combat capsulated bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.